Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth.

Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth.

Leerink analyst Daniel Clark initiated coverage of Idexx Laboratories (IDXX) with an Outperform rating and $500 price target The firm notes Idexx Laboratories is the dominant player in the ...

Learn more here. Idexx Labs has a wide array of solutions that help keep pets happy and healthy, ranging from point-of-care ...

Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. Vandana Singh Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards ...